PLA2G2A and prostate cancer: Our previous data showed that SSL and SPRL containing doxorubicin demonstrated equal potency in vitro against a panel of prostate cancer cells that had a differential expression of Group IIA sPLA2; however, SPRL were 2-fold more effective at inhibiting growth in xenograft mouse models of prostate cancer [35].